Page last updated: 2024-12-06

preclamol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Preclamol is a drug that was investigated as a potential treatment for hypertension. It acts as a calcium channel blocker, which means it prevents calcium from entering the cells of the heart and blood vessels. This effect helps to relax the blood vessels and lower blood pressure. However, Preclamol was ultimately not approved for clinical use due to concerns about its safety and efficacy. The exact reasons for its discontinued development are not widely known, likely due to its early stage of research and potential safety issues, which are common in drug development.'

preclamol: centrally acting dopamine receptor agonist with selectivity for autoreceptors [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID55445
CHEMBL ID276500
CHEBI ID125440
SCHEMBL ID872804
MeSH IDM0087067
PubMed CID5311189
CHEMBL ID7549
SCHEMBL ID1240854
MeSH IDM0087067
PubMed CID202478
CHEMBL ID7393
SCHEMBL ID8354256
MeSH IDM0087067

Synonyms (101)

Synonym
3-(3-hydroxyphenyl)-n-n-propylpiperidine
phenol, 3-(1-propyl-3-piperidinyl)-
(+)-3-(3-hydroxyphenyl)-n-(1-propyl)piperidine
n-n-propyl-3-(3-hydroxyphenyl)piperidine
3-ppp
3-(1-propyl-3-piperidinyl)phenol
OPREA1_004907
PDSP2_000175
PDSP1_000176
NCGC00162310-01
CHEBI:125440
L000832
CHEMBL276500 ,
AKOS005065963
3-(1-propylpiperidin-3-yl)phenol
ppp, r(+)-3
3ppp(+/-)
(r)-3-(1-propyl-piperidin-3-yl)-phenol
ppp, s(-)-3
nsc_202477
bdbm81924
75240-91-4
nd3ndm2ehm ,
unii-nd3ndm2ehm
BRD-A76934284-001-01-1
SCHEMBL872804
Q27216056
FT-0770905
DTXSID10861083
(+/-)-preclamol
preclamol, (+/-)-
(+/-)-3-ppp
3-ppp-(-)
PDSP1_000630
LOPAC0_000996
preclamol
PDSP2_000626
preclamol [inn]
(-)-(s)-m-(1-propyl-3-piperidyl)phenol
preclamolum [latin]
NCGC00162308-01
NCGC00162310-02
CHEMBL7549 ,
(-)-3ppp
(s)-3-(1-propylpiperidin-3-yl)phenol
bdbm50010617
(-)-3-(1-propyl-piperidin-3-yl)-phenol
3ppp,(+)
3-((s)-1-propyl-piperidin-3-yl)-phenol
unii-9v2o6crq6z
preclamolum
9v2o6crq6z ,
85966-89-8
CCG-205076
DTXSID7048453
SCHEMBL1240854
(s)-(-)-3-(3-hydroxyphenyl)-n-propylpiperidine
SDCCGSBI-0050969.P002
NCGC00162310-03
Q27273260
r-3-(3-hydroxyphenyl)-n-propylpiperidine hydrochloride
r-3-ppp hydrochloride
lopac-p-103
lopac-p-102
NCGC00015776-02
NCGC00015776-01
PDSP2_000624
LOPAC0_000986
PDSP1_000628
NCGC00162308-02
CHEMBL7393 ,
3-[(3r)-1-propylpiperidin-3-yl]phenol
(+)-3-(1-propyl-piperidin-3-yl)-phenol
3-((r)-1-propyl-piperidin-3-yl)-phenol
bdbm50010618
cid_202478
3ppp,(-)
3-(1-propyl-piperidin-3-yl)-phenol
preclamol, (r)-
85976-54-1
unii-8l7h229k4i
8l7h229k4i ,
r-3-(3-hydroxyphenyl)-n-propylpiperidine hcl
CCG-205066
SR-01000075393-11
(r)-preclamol
(r)-(+)-3-ppp
phenol, 3-((3r)-1-propyl-3-piperidinyl)-
(+)-3-ppp
(r)-(+)-3-(3-hydroxyphenyl)-n-propylpiperidine
SCHEMBL8354256
(r)-3-(3-hydroxyphenyl)-n-propylpiperidine
(r)-3-(1-propylpiperidin-3-yl)phenol
DTXSID101017364
(+)-preclamol
SDCCGSBI-0050959.P002
NCGC00162308-04
Q27270713
MS-23215
HY-145454
CS-0374747

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"3 microM and 9 microM, respectively, against the toxic action of 100 microM glutamate."( Excitatory amino acid neurotoxicity at the N-methyl-D-aspartate receptor in cultured neurons: protection by SKF 10,047.
Feuerstein, G; Lysko, PG, 1990
)
0.28

Dosage Studied

ExcerptRelevanceReference
"Irreversible inactivation of striatal D2 dopamine (DA) autoreceptors with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) or inactivation of striatal guanine nucleotide binding proteins (G proteins) with pertussis toxin (PT) shifted the dose-response curve for N-n-propylnorapomorphine (NPA)-mediated inhibition of gamma-butyrolactone (GBL)-induced elevation of L-3,4-dihydroxyphenylalanine (L-DOPA) to the right, with a decrease in the maximum response."( The effects of pertussis toxin on dopamine D2 and serotonin 5-HT1A autoreceptor-mediated inhibition of neurotransmitter synthesis: relationship to receptor reserve.
Bohmaker, K; Bordi, F; Meller, E, 1992
)
0.28
"Akin to receptor inactivation with phenoxybenzamine (PBZ) (1 microM, 1 hr), treatment of anterior pituitary cells with 17 beta-estradiol (10 nM, 3 days) right-shifted the dose-response curve for inhibition of prolactin (PRL) secretion by the full agonist R-(-)-N-n-propylnorapomorphine (NPA) and reduced the maximal effect [EC50 (pM) and percent maximal effect: control, 25."( Comparative effects of receptor inactivation, 17 beta-estradiol and pertussis toxin on dopaminergic inhibition of prolactin secretion in vitro.
Bohmaker, K; Diamond, J; Lieu, HD; Meller, E; Puza, T, 1992
)
0.28
" Furthermore, pretreatment with the drug did not affect the dose-response curve for the inhibitory effects of the DA receptor agonist apomorphine or the mixed DA agonist/sigma-receptor ligand (+)-3-(3-hydroxyphenyl)-N-1-propyl)piperidine ((+)-3-PPP)."( Sigma-receptors: implication for the control of neuronal activity of nigral dopamine-containing neurons.
Engberg, G; Wikström, H, 1991
)
0.28
" Its dose-response curve was bell-shaped with maximal effects at a dose of 100 micrograms/kg."( Occurrence of yawning and decrease of prolactin levels via stimulation of dopamine D2-receptors after administration of SND 919 in rats.
Domae, M; Furukawa, T; Matsumoto, S; Nagashima, M; Shirakawa, K; Yamada, K, 1989
)
0.28
" decreased responding to a level significantly below baseline, thus resulting in a biphasic dose-response curve."( Anxiolytic-like action of the 3-PPP enantiomers in the Vogel conflict paradigm.
Carlsson, A; Engel, JA; Hjorth, S, 1987
)
0.27
" When a dose-response was determined by administering each dose in a single bolus injection, apomorphine and (+)-3-PPP produced dose-related inhibitions of fast-firing dopaminergic neurons, with the largest dose of each compound completely inhibiting nearly all cells tested."( Effects of intraperitoneal administration of apomorphine and the isomers of 3-(1-propyl-3-piperidinyl)phenol on the firing activity of substantia nigra dopamine neurons: comparison of agonist efficacies and development of acute tolerance.
Christoffersen, CL; Meltzer, LT, 1988
)
0.27
") elicited yawning in rats and the dose-response curves of all 3 compounds showed a bell-shaped form."( Effects of apomorphine, TL-99 and 3-PPP on yawning in rats.
Boissard, CG; Delini-Stula, A; Mogilnicka, E, 1984
)
0.27
" Lever pressing for intracranial self-stimulation (ICSS) was attenuated in a dose-related fashion by TL-99 and 3-PPP, with relatively shallow dose-response relationships."( Avoidance and ICSS behavioral models dissociate TL-99 and 3-PPP from dopamine receptor antagonists.
Fenton, HM; Gerhardt, S; Hall, NR; Liebman, JM; Neale, R; Noreika, L, 1983
)
0.27
" The measured reduction in dopamine D2 receptor density after EEDQ was of the same magnitude as the reduction in receptor number predicted from the EEDQ induced shift in the dose-response curve of the full dopamine D2 receptor agonist NPA."( A high dose of EEDQ reduces pituitary dopamine D2 receptor density and the prolactin suppressive potency of agonists.
Ekman, A; Eriksson, E, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (40)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
dopamine D1 receptorHomo sapiens (human)Potency0.51740.00521.30228.1995AID624455
thioredoxin reductaseRattus norvegicus (Norway rat)Potency10.18940.100020.879379.4328AID488772; AID588453; AID588456
GLS proteinHomo sapiens (human)Potency3.54810.35487.935539.8107AID624146
regulator of G-protein signaling 4Homo sapiens (human)Potency0.16820.531815.435837.6858AID504845
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency25.11890.035520.977089.1251AID504332
D(1A) dopamine receptorHomo sapiens (human)Potency6.33910.02245.944922.3872AID488982; AID488983
dopamine D1 receptorHomo sapiens (human)Potency5.17350.00521.30228.1995AID624455
NFKB1 protein, partialHomo sapiens (human)Potency0.02510.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624146
regulator of G-protein signaling 4Homo sapiens (human)Potency0.16830.531815.435837.6858AID504845
arylsulfatase AHomo sapiens (human)Potency0.16941.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency8.91250.035520.977089.1251AID504332
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency8.49210.425612.059128.1838AID504536
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency18.01090.00106.000935.4813AID943; AID944
chaperonin GroELMethanococcus maripaludis S2Potency79.432831.622831.622831.6228AID488978
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DRattus norvegicus (Norway rat)IC50 (µMol)10.00000.00030.50267.7625AID61185
D(2) dopamine receptorBos taurus (cattle)Ki0.23840.00000.58366.1000AID62337; AID62338
D(4) dopamine receptorHomo sapiens (human)Ki0.56500.00000.436210.0000AID63849
D(3) dopamine receptorHomo sapiens (human)Ki0.16030.00000.602010.0000AID65135; AID65786
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.49540.00010.54948.4000AID62011; AID64440; AID64442
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.12000.00000.437510.0000AID65559; AID65560
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki2.10000.00020.667710.0000AID64170
D(2) dopamine receptorHomo sapiens (human)Ki0.35800.00000.651810.0000AID1391846; AID458632; AID458633; AID61172; AID61486; AID65887; AID65895
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki2.10000.00010.601710.0000AID64170
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki2.10000.00010.739610.0000AID64170
D(2) dopamine receptorBos taurus (cattle)Ki4.87670.00000.58366.1000AID64170; AID64172; AID64173
D(4) dopamine receptorHomo sapiens (human)Ki0.01600.00000.436210.0000AID61809
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki2.10000.00031.29679.2440AID64170
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Ki2.10000.00101.67479.2000AID64170
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)Ki2.10000.00101.67479.2000AID64170
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki2.10000.00020.590910.0000AID64170
5-hydroxytryptamine receptor 6Rattus norvegicus (Norway rat)Ki2.10000.00020.42542.1000AID64170
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)Ki2.10000.00000.14803.1800AID64170
5-hydroxytryptamine receptor 5ARattus norvegicus (Norway rat)Ki2.10000.30101.30032.1000AID64170
5-hydroxytryptamine receptor 5BRattus norvegicus (Norway rat)Ki2.10000.30101.30032.1000AID64170
D(3) dopamine receptorHomo sapiens (human)Ki0.07850.00000.602010.0000AID1391847; AID239943; AID64989; AID65627
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)Ki2.10000.00020.484110.0000AID64170
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)2.07030.00010.54948.4000AID63661; AID64265; AID64428; AID64429
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.19910.00000.437510.0000AID65717; AID65737; AID65738; AID65890
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)Ki2.10000.00161.02535.0119AID64170
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.23400.00000.490110.0000AID204630
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)Ki2.10000.00020.502310.0000AID64170
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)0.15990.00030.55704.2000AID229204; AID229209
DRattus norvegicus (Norway rat)IC50 (µMol)0.93000.00030.50267.7625AID62866
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.93000.00030.39075.4000AID62866
D(1B) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.93000.00030.35635.4000AID62866
D(4) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.93000.00030.38715.4000AID62866
C-8 sterol isomeraseSaccharomyces cerevisiae S288CKi1.20000.00000.90487.1500AID239296
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)12.05450.00010.54948.4000AID62866; AID63661; AID64265; AID64428; AID64429
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.18900.00000.437510.0000AID65715
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)Ki2.20000.00040.54906.7000AID239597
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.00600.00000.490110.0000AID239347
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)0.03110.00030.55704.2000AID229204; AID229209
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D(2) dopamine receptorHomo sapiens (human)EC50 (µMol)0.46100.00000.18743.9000AID1265376; AID1265381; AID1265382
D(4) dopamine receptorHomo sapiens (human)EC50 (µMol)0.06000.00140.08892.2300AID61802
D(3) dopamine receptorHomo sapiens (human)EC50 (µMol)0.03080.00010.02470.6690AID1265371; AID64816
D(2) dopamine receptorRattus norvegicus (Norway rat)EC50 (µMol)0.01900.00040.32993.9100AID61304; AID61491
mu-type opioid receptor isoform MOR-1Homo sapiens (human)EC50 (µMol)92.47000.13203.30049.5690AID720642
5-hydroxytryptamine receptor 2AMus musculus (house mouse)EC50 (µMol)76.08300.00381.36218.3930AID720643
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D(2) dopamine receptorHomo sapiens (human)Ke0.37230.36200.37230.3830AID1265380; AID1265385; AID1265386
D(2) dopamine receptorRattus norvegicus (Norway rat)Log IC500.38000.23000.30500.3800AID63992
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)Log IC500.81000.81001.16501.5200AID204628
D(2) dopamine receptorRattus norvegicus (Norway rat)Log IC500.23000.23000.30500.3800AID63992
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)Log IC501.52000.81001.16501.5200AID204628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (138)

Processvia Protein(s)Taxonomy
synaptic transmission, dopaminergicD(2) dopamine receptorBos taurus (cattle)
negative regulation of prolactin secretionD(2) dopamine receptorBos taurus (cattle)
negative regulation of lactationD(2) dopamine receptorBos taurus (cattle)
positive regulation of mammary gland involutionD(2) dopamine receptorBos taurus (cattle)
hyaloid vascular plexus regressionD(2) dopamine receptorBos taurus (cattle)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral fear responseD(4) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(4) dopamine receptorHomo sapiens (human)
response to amphetamineD(4) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
adult locomotory behaviorD(4) dopamine receptorHomo sapiens (human)
positive regulation of sodium:proton antiporter activityD(4) dopamine receptorHomo sapiens (human)
positive regulation of kinase activityD(4) dopamine receptorHomo sapiens (human)
response to histamineD(4) dopamine receptorHomo sapiens (human)
social behaviorD(4) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
fear responseD(4) dopamine receptorHomo sapiens (human)
regulation of circadian rhythmD(4) dopamine receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(4) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(4) dopamine receptorHomo sapiens (human)
rhythmic processD(4) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(4) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(4) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
inhibitory postsynaptic potentialD(4) dopamine receptorHomo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationD(4) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(4) dopamine receptorHomo sapiens (human)
chemical synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(2) dopamine receptorBos taurus (cattle)
negative regulation of prolactin secretionD(2) dopamine receptorBos taurus (cattle)
negative regulation of lactationD(2) dopamine receptorBos taurus (cattle)
positive regulation of mammary gland involutionD(2) dopamine receptorBos taurus (cattle)
hyaloid vascular plexus regressionD(2) dopamine receptorBos taurus (cattle)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral fear responseD(4) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(4) dopamine receptorHomo sapiens (human)
response to amphetamineD(4) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
adult locomotory behaviorD(4) dopamine receptorHomo sapiens (human)
positive regulation of sodium:proton antiporter activityD(4) dopamine receptorHomo sapiens (human)
positive regulation of kinase activityD(4) dopamine receptorHomo sapiens (human)
response to histamineD(4) dopamine receptorHomo sapiens (human)
social behaviorD(4) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
fear responseD(4) dopamine receptorHomo sapiens (human)
regulation of circadian rhythmD(4) dopamine receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(4) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(4) dopamine receptorHomo sapiens (human)
rhythmic processD(4) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(4) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(4) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
inhibitory postsynaptic potentialD(4) dopamine receptorHomo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationD(4) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(4) dopamine receptorHomo sapiens (human)
chemical synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
cholesterol biosynthetic process3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol metabolic process3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
hemopoiesis3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol biosynthetic process via desmosterol3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol biosynthetic process via lathosterol3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
ossification involved in bone maturation3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (22)

Processvia Protein(s)Taxonomy
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(4) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
protein bindingD(4) dopamine receptorHomo sapiens (human)
potassium channel regulator activityD(4) dopamine receptorHomo sapiens (human)
SH3 domain bindingD(4) dopamine receptorHomo sapiens (human)
dopamine bindingD(4) dopamine receptorHomo sapiens (human)
identical protein bindingD(4) dopamine receptorHomo sapiens (human)
metal ion bindingD(4) dopamine receptorHomo sapiens (human)
epinephrine bindingD(4) dopamine receptorHomo sapiens (human)
norepinephrine bindingD(4) dopamine receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityD(4) dopamine receptorHomo sapiens (human)
neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
serotonin bindingD(4) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(4) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
protein bindingD(4) dopamine receptorHomo sapiens (human)
potassium channel regulator activityD(4) dopamine receptorHomo sapiens (human)
SH3 domain bindingD(4) dopamine receptorHomo sapiens (human)
dopamine bindingD(4) dopamine receptorHomo sapiens (human)
identical protein bindingD(4) dopamine receptorHomo sapiens (human)
metal ion bindingD(4) dopamine receptorHomo sapiens (human)
epinephrine bindingD(4) dopamine receptorHomo sapiens (human)
norepinephrine bindingD(4) dopamine receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityD(4) dopamine receptorHomo sapiens (human)
neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
serotonin bindingD(4) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
C-8 sterol isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
steroid delta-isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
protein binding3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
identical protein binding3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholestenol delta-isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (38)

Processvia Protein(s)Taxonomy
Golgi membraneD(2) dopamine receptorBos taurus (cattle)
centrosomeD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
membraneD(4) dopamine receptorHomo sapiens (human)
postsynapseD(4) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
dendriteD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
Golgi membraneD(2) dopamine receptorBos taurus (cattle)
centrosomeD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
membraneD(4) dopamine receptorHomo sapiens (human)
postsynapseD(4) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
dendriteD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear envelope3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum membrane3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cytoplasmic vesicle3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
nuclear membrane3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (321)

Assay IDTitleYearJournalArticle
AID168315Evaluated for rat locomotor activity in nonhabituated rats at 213 umol / kg administered subcutaneously1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID65560Binding towards Dopamine receptor D2 using [3H]spiperone from rat striatal membrane1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID230411It is the ratio of ED50 for stimulation of locomotor activity to that of inhibition of locomotor activity1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dopamine autoreceptor agonists as potential antipsychotics. 3.6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine.
AID168030Rat locomotor activity in reserpine pretreated rats and accumulated counts / 30 min is calculated1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID138939Antagonism of apomorphine for 10-20 minutes in reserpinized mice when a dose of 33 micro mol/kg is administered intraperitoneally1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives.
AID64267Binding affinity towards dopamine receptor D2 in rat striatal membrane using [3H]spiperone1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dopamine autoreceptor agonists as potential antipsychotics. 3.6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine.
AID63849Binding towards dopamine receptor D4 expressed in CHO-K1 cells using [3H]spiperone 1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID65786Binding towards Dopamine receptor D3 expressed in CHO-K1 cells using [3H]spiperone 1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID62338Evaluated for binding towards Dopamine receptor D2 using [3H]-spiperone as radioligand, in cloned mammalian receptors expressed in CHO-K1 cells1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168318Evaluated for rat locomotor activity in nonpretreated habituated rats at 100 umol / kg1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID139078Antagonism of apomorphine in reserpinized mice when a dose of 3.3 micro mol/kg is administered intraperitoneally1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives.
AID168129Evaluated for DOPA accumulation in striatum of nonpretreated rat at 25 umol / kg administered subcutaneously1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID138772Ability to stimulate dopaminergic systems by effect on locomotor activity in reserpinized mice when a dose of 33 micro mol/kg is administered intraperitoneally1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives.
AID168659Evaluated in rat striatum for the effect on DOPAC release and metabolism in brain dialysis model after administration of 50 umol / kg subcutaneously1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168119Evaluated for DOPA accumulation in limbic region of nonpretreated rat at 25 umol / kg administered subcutaneously1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID204607Binding effinity for sigma receptor using 2 nM of [3H]DTG as radioligand, in membranes from brain minus cerebellum1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID168316Evaluated for rat locomotor activity in nonhabituated rats at 25 umol / kg1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID62011Inhibition of [3H]haloperidol binding for Dopamine receptor D2 in rat striatal membranes.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties.
AID178065Inhibition of locomotor activity was determined after (sc) administration in rat (40% inhibition was determined at 3 mg/kg)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties.
AID62337Binding towards Dopamine receptor D2 expressed in CHO-K1 cells using [3H]U-861701993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID177278ED50 value was measured as dose required to produce a half-maximal reduction of Serotonin (5-HTP) accumulation in limbic area of reserpinized rat brain; I is Inactive, no significant effect at doses approximately 40 times the ED50 for Dopa accumulation1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Monophenolic octahydrobenzo[f]quinolines: central dopamine- and serotonin-receptor stimulating activity.
AID140794In vitro inhibitory activity was determined against dopamine synthesis in mouse striatal synaptosomes1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and dopamine autoreceptor activity of a 5-(methylmercapto)methyl-substituted derivative of (+/-)-3-PPP (3-(3-hydroxyphenyl)-1-n-propylpiperidine).
AID178066Inhibition of locomotor activity was determined after oral administration in rat1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties.
AID139071Antagonism of apomorphine in reserpinized mice when a dose of 0.3 micro mol/kg is administered intraperitoneally1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives.
AID168121Evaluated for DOPA accumulation in limbic region of reserpine pretreated rat at 100 umol / kg administered intraperitoneally1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID178573Effective dose required to inhibit the Locomotor activity in Rat after po administration; NT=Not tested (ED50 mg/Kg)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dopamine autoreceptor agonists as potential antipsychotics. 3.6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine.
AID64442Inhibition of [3H]haloperidol binding for Dopamine receptor D2 in rat striatal membranes.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties.
AID177932Antagonism of apomorphine induced stereotype in rats was recorded at 30 minutes after subcutaneous administration of apomorphine1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Indolizidine and quinolizidine derivatives of the dopamine autoreceptor agonist 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP).
AID176372Contralateral circling behavior in 6-OH-DA-lesioned rats was recorded after subcutaneous administration1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Indolizidine and quinolizidine derivatives of the dopamine autoreceptor agonist 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP).
AID181024Percent reduction of hemispheres in cortex was measured in the brain of reserpinized rats; I is Inactive, no significant effect at doses approximately 40 times the ED50 for Dopa accumulation1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Monophenolic octahydrobenzo[f]quinolines: central dopamine- and serotonin-receptor stimulating activity.
AID168660Evaluated in rat striatum for the effect on dopamine release and metabolism in brain dialysis model after administration of 50 umol / kg subcutaneously1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID138910Antagonism of apomorphine for 0-10 minutes in reserpinized mice when a dose of 3.3 micro mol/kg is administered intraperitoneally1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives.
AID61185Inhibition of binding of [3H]SCH-23390 to Dopamine receptor D1 was determined1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties.
AID168655Evaluated in rat accumbens for the effect on DOPAC release and metabolism in brain dialysis model after administration of 50 umol / kg subcutaneously1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID64163Compound was evaluated for the intrinsic activity from GTP shift against dopamine receptor D21993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Centrally acting serotonergic and dopaminergic agents. 1. Synthesis and structure-activity relationships of 2,3,3a,4,5,9b-hexahydro-1H-benz[e]indole derivatives.
AID185791Percentage inhibition of DA neural firing after administration the compound at a dose of 2.5 mg/Kg through ip route in rats.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dopamine autoreceptor agonists as potential antipsychotics. 3.6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine.
AID178692Compound was tested for stimulation of locomotor activity after sc administration in rat1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dopamine autoreceptor agonists as potential antipsychotics. 3.6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine.
AID168123Evaluated for DOPA accumulation in limbic region of reserpine pretreated rat at 27 umol / kg administered subcutaneously1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID138764Ability to stimulate dopaminergic systems by effect on locomotor activity in reserpinized mice when a dose of 3.3 micro mol/kg is administered intraperitoneally1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives.
AID138932Antagonism of apomorphine for 10-20 minutes in reserpinized mice when a dose of 3.3 micro mol/kg is administered intraperitoneally1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives.
AID177121ED50 value was measured as dose required to produce a half-maximal reduction of Dopa accumulation in limbic area of reserpinized rat brain.1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Monophenolic octahydrobenzo[f]quinolines: central dopamine- and serotonin-receptor stimulating activity.
AID138757Ability to stimulate dopaminergic systems by effect on locomotor activity in reserpinized mice when a dose of 0.3 micro mol/kg is administered intraperitoneally1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives.
AID65559Evaluated for binding towards Dopamine receptor D2 using [3H]N-0437 as radioligand from rat striatal membrane1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID178247Inhibition of spontaneous locomotor activity was performed in photocell cages at 30-45 minutes after subcutaneous administration1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Indolizidine and quinolizidine derivatives of the dopamine autoreceptor agonist 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP).
AID109883Inhibitory activity was determined against inhibition of gamma-butyrolactone (GBL) induced Dopa accumulation by compound administered subcutaneously; Range 10-3201985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and dopamine autoreceptor activity of a 5-(methylmercapto)methyl-substituted derivative of (+/-)-3-PPP (3-(3-hydroxyphenyl)-1-n-propylpiperidine).
AID139086Antagonism of apomorphine in reserpinized mice when a dose of 33 micro mol/kg is administered intraperitoneally1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives.
AID176632Reversal of reserpine plus alpha-Methyl-p-tyrosine-induced hypoactivity in rats was recorded after subcutaneous administration; NT is not tested1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Indolizidine and quinolizidine derivatives of the dopamine autoreceptor agonist 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP).
AID61044In vitro binding affinity towards dopamine receptor D1 in rat striatal membrane using [3H]-SCH- 233901991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dopamine autoreceptor agonists as potential antipsychotics. 3.6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine.
AID138917Antagonism of apomorphine for 0-10 minutes in reserpinized mice when a dose of 33 micro mol/kg is administered intraperitoneally1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives.
AID204000Opioid activity in terms of inhibition of [3H]dihydromorphine binding to opioid receptor mu in rat brain membrane.1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
Binding of substituted and conformationally restricted derivatives of N-(3-phenyl-n-propyl)-1-phenyl-2-aminopropane at sigma-receptors.
AID108714Dopa accumulation induced by GBL was measured in mouse after subcutaneous administration of 32 umol/kg of compound1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and dopamine autoreceptor activity of a 5-(methylmercapto)methyl-substituted derivative of (+/-)-3-PPP (3-(3-hydroxyphenyl)-1-n-propylpiperidine).
AID138926Antagonism of apomorphine for 10-20 minutes in reserpinized mice when a dose of 0.3 micro mol/kg is administered intraperitoneally1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives.
AID178524Compound was tested for inhibition of locomotor activity after sc administration in rat1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dopamine autoreceptor agonists as potential antipsychotics. 3.6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine.
AID171358Values for the reversal of the increase in DOPA levels in the striatum of GBL-treated rats after ip administration of 10 mg/Kg1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dopamine autoreceptor agonists as potential antipsychotics. 3.6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine.
AID138782Antagonism of apomorphine for 0-10 minutes in reserpinized mice when a dose of 0.3 micro mol/kg is administered intraperitoneally1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives.
AID167996Evaluated for 5-HTP increase in hemisphere region of nonpretreated rat at 27 umol / kg administered subcutaneously1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID177284ED50 value was measured as dose required to produce a half-maximal reduction of Serotonin (5-HTP) accumulation in striatum of reserpinized rat brain; I is Inactive, no significant effect at doses approximately 40 times the ED50 for Dopa accumulation1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Monophenolic octahydrobenzo[f]quinolines: central dopamine- and serotonin-receptor stimulating activity.
AID168656Evaluated in rat accumbens for the effect on dopamine release and metabolism in brain dialysis model after administration of 50 umol / kg subcutaneously1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID64440Inhibition of [3H]N-propylnorapomorphine binding to Dopamine receptor D2 of rat striatal membranes1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties.
AID176553Decrease of DOPA formation effected by 30 mg/kg administered intraperitoneally in the striatum of GBL-treated rats1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties.
AID167999Evaluated for 5-HTP increase in limbic region of nonpretreated rat at 27 umol / kg administered subcutaneously1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID203982Displacement of [3H]DTG from sigma opioid receptor of homogenized guinea pig whole brain1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
Radiosynthesis of sigma receptor ligands for positron emission tomography: 11C- and 18F-labeled guanidines.
AID131896Effective dose required to inhibit the Locomotor activity in mouse after ip administration; NT=Not tested (ED50 mg/Kg)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dopamine autoreceptor agonists as potential antipsychotics. 3.6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine.
AID13531Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.
AID176640Reversal of reserpine-induced depression in rat after subcutaneous administration1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties.
AID65135Compound was measured for its ability to compete with [3H]spiperone binding to the human Dopamine receptor D3 transfected in CHO cells2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach.
AID177127ED50 value was measured as dose required to produce a half-maximal reduction of Dopa accumulation in the striatum of reserpinized rat brain.1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Monophenolic octahydrobenzo[f]quinolines: central dopamine- and serotonin-receptor stimulating activity.
AID493017Wombat Data for BeliefDocking2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID458634Selectivity ratio of Ki for human dopamine D2 receptor at low affinity state to Ki for human dopamine D2 receptor at high affinity state2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
AID61854Binding affinity against Dopamine receptor D1 like from bovine retina membranes measured using [3H]SCH-23390 radioligand; ND = Not determined1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and receptor binding studies.
AID173570Dose required for postsynaptic agonism using motor activity test in reserpinized rats1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
A molecular mechanics approach to the understanding of presynaptic selectivity for centrally acting dopamine receptor agonists of the phenylpiperidine series.
AID185691Level of compound in rat cerebellum at dose 45 umol/kg administered intraperitoneally1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID175375DOPA accumulation in normal rat limbic region at 213 umol/kg expressed as percent of control1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID173684Locomotor activity in normal rat at 0.8 umol/kg expressed as percent of control1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID64172Inhibition of [3H]YM-09151-2 binding to bovine retina membrane Dopamine receptor D2, high affinity site1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and receptor binding studies.
AID61491Effective concentration required for agonistic activity against rat D2 short receptor2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Fused azaindole derivatives: molecular design, synthesis and in vitro pharmacology leading to the preferential dopamine D3 receptor agonist FAUC 725.
AID1265386Antagonist activity against human D2 receptor expressed in CHO cells assessed as inhibition of dopamine-induced [35S]GTPgammaS binding at 1 uM2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treat
AID1265382Antagonist activity against human D2 receptor expressed in CHO cells assessed as dopamine EC50 at 1 uM by [35S]GTPgammaS binding assay (Rvb = 225 +/- 45 nM)2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treat
AID1391846Binding affinity to human dopamine D2 receptor
AID61809Binding affinity of compound measured using [3H]spiperone for the cloned human dopamine receptor D4.4 (high/low affinity is given as 16/1300)2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Fused azaindole derivatives: molecular design, synthesis and in vitro pharmacology leading to the preferential dopamine D3 receptor agonist FAUC 725.
AID1265381Antagonist activity against human D2 receptor expressed in CHO cells assessed as dopamine EC50 at 200 nM by [35S]GTPgammaS binding assay (Rvb = 225 +/- 45 nM)2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treat
AID185659Effect on HVA level in rat brain striatum regions at a dose of 27 uM/kg sc 60 min before death1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID61857Binding affinity for dopamine D1-like receptor labelled with [3H]SCH-23390 in retina; not determined2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Synthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand.
AID169618Evaluated biochemically in reserpine-pretreated habituated rats for (100 umol/kg) subcuteneous dose in rat striatum (DOPAacc), Value expressed as counts/30 min1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
AID61172Binding affinity of compound measured using [3H]spiperone for the cloned human dopamine receptor D2 long (high/low affinity is given as 9.0/1800)2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Fused azaindole derivatives: molecular design, synthesis and in vitro pharmacology leading to the preferential dopamine D3 receptor agonist FAUC 725.
AID175602The in vivo effect of the compound (sc injection, 227 umol/kg) on DOPA accumulation in limbic and striatal regions of reserpine-pretreated rat brains.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
On the quantitative structure-activity relationships of meta-substituted (S)-phenylpiperidines, a class of preferential dopamine D2 autoreceptor ligands: modeling of dopamine synthesis and release in vivo by means of partial least squares regression.
AID176633Reversal of reserpine plus alpha-Methyl-p-tyrosine-induced hypoactivity in rats was recorded at 1 h after administration1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Indolizidine and quinolizidine derivatives of the dopamine autoreceptor agonist 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP).
AID176539DOPA accumulation in reserpine-pretreated rat limbic region after subcutaneous administration1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID185838Level of compound in rat intraperitoneally1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID1265371Agonist activity at human D3 receptor expressed in CHO cells by [35S]GTPgammaS binding assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treat
AID194724Evaluated biochemically in reserpine-pretreated habituated rats for (100 umol/kg) subcuteneous dose, Value expressed as locomotor activity (LMA)1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
AID204628Displacement of (+)-3PPP from sigma receptor of rat brain membrane1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Molecular similarity, quantitative chirality, and QSAR for chiral drugs.
AID62328Binding affinity of compound against Dopamine receptor D2 was measured using [3H]pramipexole in Bovine striatal membranes2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Fused azaindole derivatives: molecular design, synthesis and in vitro pharmacology leading to the preferential dopamine D3 receptor agonist FAUC 725.
AID185699Level of compound in rat cortex at dose 45 umol/kg administered intraperitoneally1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID64989Binding affinity of compound measured using [3H]-spiperone for the cloned human Dopamine receptor D3 (high/low affinity is given as 25/1600)2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Fused azaindole derivatives: molecular design, synthesis and in vitro pharmacology leading to the preferential dopamine D3 receptor agonist FAUC 725.
AID176372Contralateral circling behavior in 6-OH-DA-lesioned rats was recorded after subcutaneous administration1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Indolizidine and quinolizidine derivatives of the dopamine autoreceptor agonist 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP).
AID177931Antagonism of apomorphine induced stereotype in rats was recorded at 30 minutes after subcutaneous administration apomorphine1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Indolizidine and quinolizidine derivatives of the dopamine autoreceptor agonist 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP).
AID184547Motor activity effect in reserpinized rat at 213 umol/kg, sc expressed as accumulation counts 0-30 min after treatment1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID170086Postsynaptic agonistic activity using motor activity test in reserpinized rats per 30 min1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
A molecular mechanics approach to the understanding of presynaptic selectivity for centrally acting dopamine receptor agonists of the phenylpiperidine series.
AID173915Low dose of compound giving significant reduction and increase in motor activity without pretreatment was determined; motor activity 74% of control was observed at the lowest dose1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID458632Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
AID185689Level of compound 5 in rat striatum at dose 45 umol/kg administered subcutaneously1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID185684Level of compound 5 in rat cerebellum at dose 45 umol/kg administered intraperitoneally1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID170164Effect of (60 min after administration of 200 (uM/kg) subcuteneous dose on DA release in brain dialysis model of rat striatum; Values expressed as percent of saline controls1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
AID65890Affinity against striatal dopamine D2 receptors using [3H]spiperone as radioligand in rats.1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
AID229209Binding affinity against sigma receptor1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Quantitative structure-activity relationships and eudismic analyses of the presynaptic dopaminergic activity and dopamine D2 and sigma receptor affinities of 3-(3-hydroxyphenyl)piperidines and octahydrobenzo[f]quinolines.
AID189818post-synaptic dopaminergic effect was assessed by the increase in locomotor activity at 30 min time interval by 213 umol/kg dosage administration1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors.
AID178249Inhibition of spontaneous locomotor activity was performed in photocell cages. Motility was measured at 30-40 minutes after subcutaneous administration; value ranges from 4.2-111987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Indolizidine and quinolizidine derivatives of the dopamine autoreceptor agonist 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP).
AID185839Level of compound in rat striatum at dose 45 umol/kg administered subcutaneously1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID1265375Selectivity ratio of EC50 for human D2 receptor expressed in CHO cells to EC50 for human D3 receptor expressed in CHO cells2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treat
AID194723Evaluated biochemically in nonpretreated habituated rats for (100 uM/kg) subcuteneous dose, Value expressed as locomotor activity (LMA)1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
AID170269Motor activity with reserpine pretreatment at dose 213 uM/kg1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID173492Half-maximal decrease of DOPA accumulation (no reserpine pretreatment) in the striatum of rat brain at dose 27 uM/kg1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID232104Ratio of binding affinities for dopamine transporter over sigma-1 receptor2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
AID173483Half-maximal decrease of DOPA accumulation (no reserpine pretreatment) in the limbic system of rat brain at dose 213 uM/kg1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID194722Evaluated biochemically in nonhabituated rats for (100 umol/kg) subcuteneous dose, Value expressed as locomotor activity (LMA)1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
AID174026Presynaptic activity at the level of DA metabolism was determined at dose 45 umol/kg on striatal level of HVA1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID232373Ratio of D2-D3 like receptor to D4 like receptor2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Synthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand.
AID176558Dopa accumulation was evaluated in corpus striatum of male Sprague-Dawley rat1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID62706Presynaptic agonistic activity against dopamine receptor in limbic system1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
A molecular mechanics approach to the understanding of presynaptic selectivity for centrally acting dopamine receptor agonists of the phenylpiperidine series.
AID65737In vitro binding affinity to rat striatal Dopamine receptor D2 was determined using the agonist [3H]quinpirole to label the high affinity state (D2 high)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans.
AID170165Effect on extracellular DA levels in the striatal region of rat brain.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
On the quantitative structure-activity relationships of meta-substituted (S)-phenylpiperidines, a class of preferential dopamine D2 autoreceptor ligands: modeling of dopamine synthesis and release in vivo by means of partial least squares regression.
AID229204In vitro for binding affinity against sigma receptor using [3H](+)-3-PPP as radioligand1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors.
AID197520In vivo presynaptic dopaminergic potency, determined by the ability to reduce the accumulation of DOPA by 50%1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Quantitative structure-activity relationships and eudismic analyses of the presynaptic dopaminergic activity and dopamine D2 and sigma receptor affinities of 3-(3-hydroxyphenyl)piperidines and octahydrobenzo[f]quinolines.
AID65738In vitro binding affinity to rat striatal Dopamine receptor D2 was determined using the antagonist [3H]spiperone + GTP to label the low affinity state (D2 low)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans.
AID1265370Agonist activity at human D3 receptor expressed in CHO cells by [35S]GTPgammaS binding assay relative to dopamine2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treat
AID65627Tested for in vitro binding affinity against cloned mammalian dopamine D3 receptor, expressed in CHO-K1 cells, using [3H]spiperone as radioligand1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
AID1265380Antagonist activity against human D2 receptor expressed in CHO cells assessed as inhibition of dopamine-induced [35S]GTPgammaS binding2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treat
AID234956Selectivity pIC50 (sigma)-pIC50(D2)1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Quantitative structure-activity relationships and eudismic analyses of the presynaptic dopaminergic activity and dopamine D2 and sigma receptor affinities of 3-(3-hydroxyphenyl)piperidines and octahydrobenzo[f]quinolines.
AID64816Effective concentration required for agonistic activity against human D3 receptor2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Fused azaindole derivatives: molecular design, synthesis and in vitro pharmacology leading to the preferential dopamine D3 receptor agonist FAUC 725.
AID184549Motor activity effect in reserpinized rat with tropolone pretreatment at 10 umol/kg, ip expressed as accumulation counts 0-30 min after treatment1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID230928Ratio of the binding affinity to low affinity state (D2 low) to high affinity state (D2 high)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans.
AID65717In vitro affinity against dopamine receptor D2 using [3H]DP-5,6-ADTN radioligand in rat striatal homogenate1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID185658Effect on HVA level in rat brain limbic regions at a dose of 27 uM/kg sc 60 min before death1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID176546DOPA accumulation in reserpine-pretreated rat striatal region after subcutaneous administration1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID63992Displacement of spiperone from dopamine receptor D2 of rat brain membrane1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Molecular similarity, quantitative chirality, and QSAR for chiral drugs.
AID176538DOPA accumulation in reserpine-pretreated rat cortex after subcutaneous administration; Inactive1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID239943Inhibition constant against [3H]-spiperone binding to human Dopamine receptor D3 expressed in CHO cells2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
CoMFA and CoMSIA investigations revealing novel insights into the binding modes of dopamine D3 receptor agonists.
AID176584Half-maximal decrease of DOPA accumulation upon reserpine pretreatment in the corpus striatum of rat brain1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID64170Tested for binding affinity against Dopamine receptor D2 like from bovine striatum membranes by using [3H]YM-09151-2 radioligand1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and receptor binding studies.
AID458635Activity at dopamine D2L receptor expressed in HEK293 cells coexpressing Galphaqi5 assessed as maximal efficacy relative to control2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
AID185692Level of compound in rat cerebellum at dose 45 umol/kg administered subcutaneously1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID175368DOPA accumulation in normal rat cortex at 27 umol/kg expressed as percent of control; Inactive1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID178250Inhibition of spontaneous locomotor activity was performed in photocell cages. Motility was measured at 5 minutes1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Indolizidine and quinolizidine derivatives of the dopamine autoreceptor agonist 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP).
AID64302Binding affinity for dopamine D2-D3 like receptor labelled with [3H]YM-09151-2 in striatum2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Synthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand.
AID185687Level of compound 5 in rat cortex at dose 45 umol/kg administered subcutaneously1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID185686Level of compound 5 in rat cortex at dose 45 umol/kg administered intraperitoneally1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID185688Level of compound 5 in rat intraperitoneally1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID64429In vitro inhibition of [3H]spiperone binding to Dopamine receptor D2 in rat striatal membranes1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID63651Tested in vivo for binding affinity against Dopamine receptor D2 using nonradiolabeled 5,6-di-n-Pr-ADTN1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors.
AID62709Presynaptic agonistic activity against dopamine receptor in striatum1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
A molecular mechanics approach to the understanding of presynaptic selectivity for centrally acting dopamine receptor agonists of the phenylpiperidine series.
AID65895In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
AID61384Ability to displace [3H]spiroperidol, from dopamine receptor D2 specific binding sites of rat striatal membranes1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Oxygen isosteric derivatives of 3-(3-hydroxyphenyl)-N-n-propylpiperidine.
AID169627Evaluated for DOPAC level in nonpretreated habituated rats after subcuteneous dose of 100 micro mol/kg in rat striatum1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
AID169620Evaluated for DOPA accumulation (DOPAacc) level in nonhabituated rats after subcuteneous dose (100 uM/kg) in rat striatum1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
AID458631Reduction in 3,4-dihydroxyphenylacetic acid level in Sprague-Dawley rat striatum at 117 umol/kg, sc relative to saline treated control2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
AID175367DOPA accumulation in normal rat cortex at 213 umol/kg expressed as percent of control; Inactive1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID1265377Agonist activity at human D2 receptor expressed in CHO cells by [35S]GTPgammaS binding assay relative to dopamine2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treat
AID186196Locomotor activity in reserpine-pretreated ratat the dose of 213 umol/kg; Accumulation counts/30 min1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID65191Binding affinity against dopamine transporter was determined by the displacement of [3H]WIN-35428 radioligand in rat brain2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
AID458646Reduction in spontaneous locomotor activity in Sprague-Dawley rat striatum at 117 umol/kg, sc relative to control2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
AID23982Apparent lipophilicity (log kw) at pH 7.51987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Quantitative structure-activity relationships and eudismic analyses of the presynaptic dopaminergic activity and dopamine D2 and sigma receptor affinities of 3-(3-hydroxyphenyl)piperidines and octahydrobenzo[f]quinolines.
AID64173Inhibition of [3H]YM-09151-2 binding to bovine retina membrane Dopamine receptor D2, low affinity site1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and receptor binding studies.
AID458633Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
AID64428In vitro inhibition of [3H]N-0437 binding to Dopamine receptor D2 in rat striatal membranes1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID63853Binding affinity for dopamine D4-like receptor labelled with [3H]YM-09151-2 in retina2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Synthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand.
AID176585Half-maximal decrease of DOPA accumulation upon reserpine pretreatment in the limbic system of rat brain1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID176560Dopa accumulation was evaluated in limbic system of male Sprague-Dawley rat1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID61486Binding affinity of compound measured using [3H]spiperone for the cloned human dopamine receptor D2 short (high/low affinity is given as 27/1800)2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Fused azaindole derivatives: molecular design, synthesis and in vitro pharmacology leading to the preferential dopamine D3 receptor agonist FAUC 725.
AID64265Binding affinity against Dopamine receptor D2 using [3H]spiperone as radioligand1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors.
AID204630Binding affinity against Sigma receptor type 1 was determined by the displacement of [3H]pentazocine radioligand2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
AID1391847Binding affinity to human dopamine D3 receptor
AID173820Locomotor activity in normal rat at 213 umol/kg expressed as percent of control1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID184694Motor activity effect in reserpinized rat with tropolone pretreatment at 50 umol/kg, ip expressed as accumulation counts 0-30 min after treatment1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID1265385Antagonist activity against human D2 receptor expressed in CHO cells assessed as inhibition of dopamine-induced [35S]GTPgammaS binding at 200 nM2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treat
AID178409Effective dose required for DOPA accumulation (presynaptic dopaminergic effect) in rat1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors.
AID185657Effect on DOPAC level in rat brain striatum regions at a dose of 27 uM/kg sc 60 min before death1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID174025Presynaptic activity at the level of DA metabolism was determined at dose 45 umol/kg on striatal level of DOPAC1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID4336Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
AID61304Effective concentration required for agonistic activity against rat D2 long receptor2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Fused azaindole derivatives: molecular design, synthesis and in vitro pharmacology leading to the preferential dopamine D3 receptor agonist FAUC 725.
AID65887Affinity against recombinant dopamine receptor (DA) D2 expressed in CHO-K1 cells, using [3H]-spiperone as radioligand1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
AID185700Level of compound in rat cortex at dose 45 umol/kg administered subcutaneously1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID175523DOPA accumulation in normal rat striatal region at 27 umol/kg expressed as percent of control1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID175517DOPA accumulation in normal rat limbic region at 27 umol/kg expressed as percent of control; Inactive1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID63661Binding affinity for dopamine receptor D2 was evaluated by the ability to displace [3H]spiperone1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Quantitative structure-activity relationships and eudismic analyses of the presynaptic dopaminergic activity and dopamine D2 and sigma receptor affinities of 3-(3-hydroxyphenyl)piperidines and octahydrobenzo[f]quinolines.
AID173740High dose of compound giving significant reduction and increase in motor activity without pretreatment was determined; motor activity 40% of control was observed at the highest dose1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID1265376Agonist activity at human D2 receptor expressed in CHO cells by [35S]GTPgammaS binding assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treat
AID175604In vivo effect on DOPA accumulation in limbic and striatal regions of the rat brain without reserpine pretreatment1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
On the quantitative structure-activity relationships of meta-substituted (S)-phenylpiperidines, a class of preferential dopamine D2 autoreceptor ligands: modeling of dopamine synthesis and release in vivo by means of partial least squares regression.
AID185685Level of compound 5 in rat cerebellum at dose 45 umol/kg administered subcutaneously1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID185656Effect on DOPAC level in limbic system of rat brain at a dose of 27 uM/kg sc 60 min before death1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID63185Binding affinity of compound measured against Dopamine receptor D1 from bovine striatal membranes using radioligand [3H]-SCH- 23390; ND means not determined2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Fused azaindole derivatives: molecular design, synthesis and in vitro pharmacology leading to the preferential dopamine D3 receptor agonist FAUC 725.
AID61802Effective concentration required for agonistic activity against human D4.2 receptor2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Fused azaindole derivatives: molecular design, synthesis and in vitro pharmacology leading to the preferential dopamine D3 receptor agonist FAUC 725.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID193713DA2 antagonist activity was tested by its ability to decrease the arterial pressure in anesthetized rat at 30 ug/kg1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
2,5-Dimethoxy congeners of (+)-and (-)-3-(3-hydroxyphenyl)-N-n- propylpiperidine.
AID170086Postsynaptic agonistic activity using motor activity test in reserpinized rats per 30 min1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
A molecular mechanics approach to the understanding of presynaptic selectivity for centrally acting dopamine receptor agonists of the phenylpiperidine series.
AID193710DA2 antagonist activity was tested by its ability to decrease the arterial pressure in anesthetized rat at 10 ug/kg1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
2,5-Dimethoxy congeners of (+)-and (-)-3-(3-hydroxyphenyl)-N-n- propylpiperidine.
AID193560DA2 antagonist activity was tested by its ability to decrease the heart rate in anesthetized rat at 100 ug/kg1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
2,5-Dimethoxy congeners of (+)-and (-)-3-(3-hydroxyphenyl)-N-n- propylpiperidine.
AID64428In vitro inhibition of [3H]N-0437 binding to Dopamine receptor D2 in rat striatal membranes1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID173916Low dose of compound giving significant reduction and increase in motor activity without pretreatment was determined; motor activity 75% of control was observed at the lowest dose1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID63661Binding affinity for dopamine receptor D2 was evaluated by the ability to displace [3H]spiperone1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Quantitative structure-activity relationships and eudismic analyses of the presynaptic dopaminergic activity and dopamine D2 and sigma receptor affinities of 3-(3-hydroxyphenyl)piperidines and octahydrobenzo[f]quinolines.
AID185658Effect on HVA level in rat brain limbic regions at a dose of 27 uM/kg sc 60 min before death1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID193559DA2 antagonist activity was tested by its ability to decrease the heart rate in anesthetized rat at 10 ug/kg1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
2,5-Dimethoxy congeners of (+)-and (-)-3-(3-hydroxyphenyl)-N-n- propylpiperidine.
AID229203Eudisimic index was determined for the compound against sigma receptor1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Quantitative structure-activity relationships and eudismic analyses of the presynaptic dopaminergic activity and dopamine D2 and sigma receptor affinities of 3-(3-hydroxyphenyl)piperidines and octahydrobenzo[f]quinolines.
AID62706Presynaptic agonistic activity against dopamine receptor in limbic system1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
A molecular mechanics approach to the understanding of presynaptic selectivity for centrally acting dopamine receptor agonists of the phenylpiperidine series.
AID63853Binding affinity for dopamine D4-like receptor labelled with [3H]YM-09151-2 in retina2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Synthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand.
AID176372Contralateral circling behavior in 6-OH-DA-lesioned rats was recorded after subcutaneous administration1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Indolizidine and quinolizidine derivatives of the dopamine autoreceptor agonist 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP).
AID174026Presynaptic activity at the level of DA metabolism was determined at dose 45 umol/kg on striatal level of HVA1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID173820Locomotor activity in normal rat at 213 umol/kg expressed as percent of control1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID175364DOPA accumulation in normal rat cortex at 0.8 umol/kg expressed as percent of control; Inactive1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID192379post-synaptic dopaminergic effect was assessed by the increase in locomotor activity at 30 min time interval by 13 umol/kg dosage administration1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors.
AID178251Inhibition of spontaneous motility was measured 5 min after subcutaneous administration is 2.4; ND means no data1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Indolizidine and quinolizidine derivatives of the dopamine autoreceptor agonist 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP).
AID183234Inhibition of dopamine neuronal firing in the anesthetized rats after ip administration at a dose 2.5 mg/kg1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Dopamine autoreceptor agonists as potential antipsychotics. 1. (Aminoalkoxy)anilines.
AID173488Half-maximal decrease of DOPA accumulation (no reserpine pretreatment) in the striatum of rat brain at dose 0.8 uM/kg1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID176560Dopa accumulation was evaluated in limbic system of male Sprague-Dawley rat1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID176633Reversal of reserpine plus alpha-Methyl-p-tyrosine-induced hypoactivity in rats was recorded at 1 h after administration1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Indolizidine and quinolizidine derivatives of the dopamine autoreceptor agonist 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP).
AID204616Inhibition of [3H]NANM binding to sigma receptor obtained from tissue homogenate preparation of fresh whole rat brain minus cerebellum1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Rigid phencyclidine analogues. Binding to the phencyclidine and sigma 1 receptors.
AID64429In vitro inhibition of [3H]spiperone binding to Dopamine receptor D2 in rat striatal membranes1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID64302Binding affinity for dopamine D2-D3 like receptor labelled with [3H]YM-09151-2 in striatum2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Synthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand.
AID176585Half-maximal decrease of DOPA accumulation upon reserpine pretreatment in the limbic system of rat brain1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID175121DA2 antagonist activity was tested by the duration of onset of action of cardiovascular response at 30 ug/kg1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
2,5-Dimethoxy congeners of (+)-and (-)-3-(3-hydroxyphenyl)-N-n- propylpiperidine.
AID175520DOPA accumulation in normal rat striatal region at 0.8 umol/kg expressed as percent of control1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID234956Selectivity pIC50 (sigma)-pIC50(D2)1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Quantitative structure-activity relationships and eudismic analyses of the presynaptic dopaminergic activity and dopamine D2 and sigma receptor affinities of 3-(3-hydroxyphenyl)piperidines and octahydrobenzo[f]quinolines.
AID239347Affinity for sigma receptor type 1 of guinea pig using [3H]ifenprodil or (+)-[3H]pentazocine radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID173478Half-maximal decrease of DOPA accumulation (no reserpine pretreatment) in the limbic system of rat brain at dose 0.8 uM/kg1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID175523DOPA accumulation in normal rat striatal region at 27 umol/kg expressed as percent of control1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID156836Inhibition of binding to PCP receptor obtained from tissue homogenate preparation of fresh whole rat brain minus cerebellum1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Rigid phencyclidine analogues. Binding to the phencyclidine and sigma 1 receptors.
AID175376DOPA accumulation in normal rat limbic region at 27 umol/kg expressed as percent of control1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID65715In vitro affinity against Dopamine receptor D2 using [3H]DP-5,6-ADTN radioligand in rat striatal homogenate1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID63992Displacement of spiperone from dopamine receptor D2 of rat brain membrane1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Molecular similarity, quantitative chirality, and QSAR for chiral drugs.
AID232373Ratio of D2-D3 like receptor to D4 like receptor2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Synthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand.
AID185685Level of compound 5 in rat cerebellum at dose 45 umol/kg administered subcutaneously1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID186195Locomotor activity in reserpine-pretreated ratat the dose of 13 umol/kg; Accumulation counts/30 min1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID185838Level of compound in rat intraperitoneally1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID61242Eudisimic index was determined for the compound against Dopamine receptor D21987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Quantitative structure-activity relationships and eudismic analyses of the presynaptic dopaminergic activity and dopamine D2 and sigma receptor affinities of 3-(3-hydroxyphenyl)piperidines and octahydrobenzo[f]quinolines.
AID185699Level of compound in rat cortex at dose 45 umol/kg administered intraperitoneally1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID229204In vitro for binding affinity against sigma receptor using [3H](+)-3-PPP as radioligand1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors.
AID204628Displacement of (+)-3PPP from sigma receptor of rat brain membrane1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Molecular similarity, quantitative chirality, and QSAR for chiral drugs.
AID23982Apparent lipophilicity (log kw) at pH 7.51987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Quantitative structure-activity relationships and eudismic analyses of the presynaptic dopaminergic activity and dopamine D2 and sigma receptor affinities of 3-(3-hydroxyphenyl)piperidines and octahydrobenzo[f]quinolines.
AID178064Inhibition of locomotor activity in rats, after sc injection after dosing for a period of 30 min1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Dopamine autoreceptor agonists as potential antipsychotics. 1. (Aminoalkoxy)anilines.
AID64265Binding affinity against Dopamine receptor D2 using [3H]spiperone as radioligand1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors.
AID62866In vitro inhibition of [3H]haloperidol (HPD) binding to dopamine (DA) receptor of rat striatal membranes1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Dopamine autoreceptor agonists as potential antipsychotics. 1. (Aminoalkoxy)anilines.
AID185659Effect on HVA level in rat brain striatum regions at a dose of 27 uM/kg sc 60 min before death1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID193993Effect on DOPAC level in limbic system of rat brain at a dose of 27 uM/kg sc 60 min before death1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID185686Level of compound 5 in rat cortex at dose 45 umol/kg administered intraperitoneally1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID193562DA2 antagonist activity was tested by its ability to decrease the heart rate in anesthetized rat at 30 ug/kg1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
2,5-Dimethoxy congeners of (+)-and (-)-3-(3-hydroxyphenyl)-N-n- propylpiperidine.
AID233109Ratio of reversal of 6-OHDA-induced depression to inhibition of locomotor activity1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Dopamine autoreceptor agonists as potential antipsychotics. 1. (Aminoalkoxy)anilines.
AID176539DOPA accumulation in reserpine-pretreated rat limbic region after subcutaneous administration1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID185689Level of compound 5 in rat striatum at dose 45 umol/kg administered subcutaneously1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID175372DOPA accumulation in normal rat limbic region at 0.8 umol/kg expressed as percent of control1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID173817Locomotor activity in normal rat at 1.6 umol/kg expressed as percent of control1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID193711DA2 antagonist activity was tested by its ability to decrease the arterial pressure in anesthetized rat at 100 ug/kg1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
2,5-Dimethoxy congeners of (+)-and (-)-3-(3-hydroxyphenyl)-N-n- propylpiperidine.
AID176626Reversal of 6-OHDA-induced depression in rats, after sc injection after dosing for a period of 30 min1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Dopamine autoreceptor agonists as potential antipsychotics. 1. (Aminoalkoxy)anilines.
AID176538DOPA accumulation in reserpine-pretreated rat cortex after subcutaneous administration; Inactive1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID239597Affinity for human EMP expressed in ERG2 deficient strain of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine as radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID185688Level of compound 5 in rat intraperitoneally1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID176558Dopa accumulation was evaluated in corpus striatum of male Sprague-Dawley rat1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID170275Motor activity with reserpine pretreatment at dose 13 uM/kg1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID63651Tested in vivo for binding affinity against Dopamine receptor D2 using nonradiolabeled 5,6-di-n-Pr-ADTN1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors.
AID233110Ratio of reversal of reserpine-induced depression to inhibition of locomotor activity1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Dopamine autoreceptor agonists as potential antipsychotics. 1. (Aminoalkoxy)anilines.
AID185845Level of compound in rat striatum at dose 45 umol/kg administered subcutaneously.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID185687Level of compound 5 in rat cortex at dose 45 umol/kg administered subcutaneously1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID62709Presynaptic agonistic activity against dopamine receptor in striatum1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
A molecular mechanics approach to the understanding of presynaptic selectivity for centrally acting dopamine receptor agonists of the phenylpiperidine series.
AID229209Binding affinity against sigma receptor1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Quantitative structure-activity relationships and eudismic analyses of the presynaptic dopaminergic activity and dopamine D2 and sigma receptor affinities of 3-(3-hydroxyphenyl)piperidines and octahydrobenzo[f]quinolines.
AID185700Level of compound in rat cortex at dose 45 umol/kg administered subcutaneously1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID185657Effect on DOPAC level in rat brain striatum regions at a dose of 27 uM/kg sc 60 min before death1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID185684Level of compound 5 in rat cerebellum at dose 45 umol/kg administered intraperitoneally1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID185691Level of compound in rat cerebellum at dose 45 umol/kg administered intraperitoneally1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID61857Binding affinity for dopamine D1-like receptor labelled with [3H]SCH-23390 in retina; not determined2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Synthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand.
AID177880Inhibition of accumulation of DOPA in rat striatum, after intraperitoneal administration.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Dopamine autoreceptor agonists as potential antipsychotics. 1. (Aminoalkoxy)anilines.
AID239296Affinity for ERG2 of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID175116DA2 antagonist activity was tested by the duration of onset of action of cardiovascular response at 10 ug/kg1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
2,5-Dimethoxy congeners of (+)-and (-)-3-(3-hydroxyphenyl)-N-n- propylpiperidine.
AID184546Motor activity effect in reserpinized rat at 13 umol/kg, sc expressed as accumulation counts 0-30 min after treatment1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID175117DA2 antagonist activity was tested by the duration of onset of action of cardiovascular response at 100 ug/kg1993Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16
2,5-Dimethoxy congeners of (+)-and (-)-3-(3-hydroxyphenyl)-N-n- propylpiperidine.
AID178063Inhibition of locomotor activity in rats after peroral administration of the compound.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Dopamine autoreceptor agonists as potential antipsychotics. 1. (Aminoalkoxy)anilines.
AID176584Half-maximal decrease of DOPA accumulation upon reserpine pretreatment in the corpus striatum of rat brain1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID178409Effective dose required for DOPA accumulation (presynaptic dopaminergic effect) in rat1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors.
AID185692Level of compound in rat cerebellum at dose 45 umol/kg administered subcutaneously1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID177932Antagonism of apomorphine induced stereotype in rats was recorded at 30 minutes after subcutaneous administration of apomorphine1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Indolizidine and quinolizidine derivatives of the dopamine autoreceptor agonist 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP).
AID173570Dose required for postsynaptic agonism using motor activity test in reserpinized rats1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
A molecular mechanics approach to the understanding of presynaptic selectivity for centrally acting dopamine receptor agonists of the phenylpiperidine series.
AID174025Presynaptic activity at the level of DA metabolism was determined at dose 45 umol/kg on striatal level of DOPAC1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
AID173739High dose of compound giving significant reduction and increase in motor activity without pretreatment was determined; motor activity 230% of control was observed at the highest dose1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity.
AID175368DOPA accumulation in normal rat cortex at 27 umol/kg expressed as percent of control; Inactive1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID197520In vivo presynaptic dopaminergic potency, determined by the ability to reduce the accumulation of DOPA by 50%1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Quantitative structure-activity relationships and eudismic analyses of the presynaptic dopaminergic activity and dopamine D2 and sigma receptor affinities of 3-(3-hydroxyphenyl)piperidines and octahydrobenzo[f]quinolines.
AID176546DOPA accumulation in reserpine-pretreated rat striatal region after subcutaneous administration1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (369)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990164 (44.44)18.7374
1990's162 (43.90)18.2507
2000's19 (5.15)29.6817
2010's19 (5.15)24.3611
2020's5 (1.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.20 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials5 (1.38%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews7 (1.93%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
Other351 (96.69%)84.16%
Other24 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]